OTX-TKI: Inside the SOL-1 Data - Top-Institutions - MDSpire

OTX-TKI: Inside the SOL-1 Data

At ASRS 2026, Dilsher S. Dhoot, MD, FASRS, shared additional phase 3 SOL-1 data on vision maintenance, rescue treatment, and safety with investigational OTX-TKI (Axpaxli) in neovascular AMD.

  • By

  • Dilsher S. Dhoot, MD

  • July 15, 2026

  • 3 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic Lerner College of Medicine
    Cleveland Clinic Lerner College of Medicine

    Cleveland, Ohio

    Key Differentiators

    • Oncology

  • #2

    Sierra Eye Associates
    Sierra Eye Associates

    Sierra Vista, Arizona

    Key Differentiators

    • Ophthalmology

  • #3

    Cole Eye Institute
    Cole Eye Institute

    Cleveland, Ohio

    Key Differentiators

    • Ophthalmology

  • #4

    Vall d’Hebron Institute of Oncology
    Vall d’Hebron Institute of Oncology

    Barcelona, Catalonia

    Key Differentiators

    • Oncology

  • #5

    Association for Research in Vision and Ophthalmology
    Association for Research in Vision and Ophthalmology

    Rockville, Maryland

    Key Differentiators

    • Ophthalmology

Original Source(s)

OTX-TKI: Inside the SOL-1 Data

  • by Dilsher S. Dhoot, MD

  • July 15, 2026

Related Content

Elevated GDF15 in ocular fluids of patients with proliferative diabetic retinopathy

The Economics of Home OCT

At ASRS 2026, Sean Berkowitz, MD, MBA, examined the payer costs and physician workload associated with home OCT monitoring for wet AMD.

Systemic factors associated with poor anatomical response to anti-VEGF therapy in patients with diabetic macular edema: evidence from a large clinical cohort